SITEONE THERAPEUTICS, INC.

Bozeman, MT · Founded 2014 · Biotech · Acquired

Small molecule NaV1.7 ion channel inhibitors for chronic cough treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Bozeman, MT
Founded: 2014
Latest Form D: $14.9M, Feb 2017
Total capital: $28.2M

Federal grants: $12M; 13 awards · 2015–2022; Rank in peer group#36 of 514
Private capital raised: $16.1M; 2 Form D · last Feb 2017; 116 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 13 pending · first 2024; Rank in peer group#186 of 514

Capital timeline

Latest events

Sep 2022Federal grantHealth and Human S · Phase II · Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$560K
Apr 2022Federal grantHealth and Human S · Phase II · Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$1.1M
Sep 2021Federal grantHealth and Human S · Phase II · Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$1.6M
May 2021Federal grantHealth and Human S · Phase II · Discovery of NaV1.7 Inhibitors for the Treatment of Pain$456K
May 2021Federal grantHealth and Human S · Phase II · Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$1.7M
Aug 2019Federal grantHealth and Human S · Phase II · Guanidinium Derivatives For The Treatment Of Ocular Pain$889K
May 2019Federal grantHealth and Human S · Phase I · Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough$324K
Feb 2017Private capital raisedForm D · SEC · 2nd filing$14.9M
Jul 2015Private capital raisedForm D · SEC · 1st filing$1.3M

Show 6 earlier federal awards

Sep 2018Federal grantHealth and Human S · Phase II · Guanidinium Derivatives For The Treatment Of Ocular Pain$1.5M
Aug 2017Federal grantHealth and Human S · Phase II · Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$829K
Sep 2016Federal grantHealth and Human S · Phase II · Development of Selective Inhibitors of NaV as Therapeutics for Pain$1.4M
Jul 2016Federal grantHealth and Human S · Phase II · Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$617K
Sep 2015Federal grantHealth and Human S · Phase II · Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$756K
Aug 2015Federal grantHealth and Human S · Phase I · Guanidinium Derivatives for the Treatment of Ocular Pain$224K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#36 · top 7%
Granted patents#186 · top 36%
Linked publications#88 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

John E. MulcahyResearcherExecutive OfficerLinked by $1.9M in grants as PI
George MiljanichExecutive OfficerNamed in SEC Form D filings
Joseph E. ZakrzewskiDirectorNamed in SEC Form D filings
Justin DuBoisDirectorNamed in SEC Form D filings
Justin E. Du BoisDirectorNamed in SEC Form D filings
Lowell E. SearsDirectorNamed in SEC Form D filings

Show all 9 people

Rick E. OrrDirectorNamed in SEC Form D filings
Stan E. AbelExecutive Officer, DirectorNamed in SEC Form D filings
Will E. PriceDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 14

Dec 10, 2024Granted11,13-MODIFIED Saxitoxins For The Treatment Of PainUSPTOUS 12,162,886
Oct 26, 2023PendingNon-hydrated Ketone Inhibitors Of NAV1.7 For The Treatment Of PainUSPTOApplication 18041523
Pending2-ARYL CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAINUSPTOApplication 63712366

Show all 14 patent records

11,13-MODIFIED Saxitoxins For The Treatment Of PainDec 10, 2024 · US 12,162,886Granted
Non-hydrated Ketone Inhibitors Of NAV1.7 For The Treatment Of PainOct 26, 2023 · Application 18041523Pending
2-ARYL CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAINApplication 63712366Pending
BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAINApplication 18859770Pending
Substituted Cycloalkyl And Heterocycloalkyl Inhibitors Of NAV1.8 For The Treatment Of PainApplication 63649161Pending
2-ARYL Cycloalkyl And Heterocycloalkyl Inhibitors Of NAV1.8 For The Treatment Of PainApplication 63624672Pending
Bicyclic Heterocyclic Amide Inhibitors Of Na V1.8 For The Treatment Of PainApplication PCTUS2023019879Pending
Non-hydrated Ketone Inhibitors Of NAV1.7 For The Treatment Of PainApplication PCTUS2021046054Pending
Non-hydrated Ketone Inhibitors Of NAV1.7 For The Treatment Of PainApplication 63066012Pending
11,13-MODIFIED Saxitoxins For The Treatment Of PainApplication PCTUS2019054588Pending
11,13-MODIFIED Saxitoxins For The Treatment Of PainApplication 62740711Pending
Substituted Cycloalkyl And Heterocycloalkyl Inhibitors Of NAV1.8 For The Treatment Of PainApplication PCTUS2025029820Pending
11,13-MODIFIED Saxitoxins For The Treatment Of PainApplication 62478523Pending
2-ARYL Cycloalkyl And Heterocycloalkyl Inhibitors Of NAV1.8 For The Treatment Of PainApplication PCTUS2025012773Pending

Recent research by its founders

Structural basis for saxitoxin congener binding and neutralization by anuran saxiphilins20256 cites
BPS2025 - Structural basis for saxitoxin congener binding and neutralization by anuran saxiphilins20250 cites
ST‐2560, a selective inhibitor of the Na<sub>V</sub>1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non‐human primates202417 cites

PARTILLION BIOSCIENCE CORPORATIONSimilar federal contract value in Biotech · null in contracts
Design Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
CARDIAC RSK3 INHIBITORS, LLCSimilar federal contract value in Biotech · null in contracts
Rattan Life Science Inc.Similar federal contract value in Biotech · null in contracts
CAPTOZYME, INC.Similar federal contract value in Biotech · null in contracts
Mimetics, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.